Jazz Pharmaceuticals Statistics
Share Statistics
Jazz Pharmaceuticals has 61.63M
shares outstanding. The number of shares has increased by -3.69%
in one year.
| Shares Outstanding | 61.63M |
| Shares Change (YoY) | -3.69% |
| Shares Change (QoQ) | 0.46% |
| Owned by Institutions (%) | 96.17% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 21,931 |
| FTD / Avg. Volume | 1.66% |
Short Selling Information
The latest short interest is 5.95M, so 9.66% of the outstanding
shares have been sold short.
| Short Interest | 5.95M |
| Short % of Shares Out | 9.66% |
| Short % of Float | 11.13% |
| Short Ratio (days to cover) | 3.6 |
Valuation Ratios
The PE ratio is 13.6 and the forward
PE ratio is 4.96.
Jazz Pharmaceuticals's PEG ratio is
0.45.
| PE Ratio | 13.6 |
| Forward PE | 4.96 |
| PS Ratio | 1.87 |
| Forward PS | 1.3 |
| PB Ratio | 1.86 |
| P/FCF Ratio | 5.65 |
| PEG Ratio | 0.45 |
Financial Ratio HistoryEnterprise Valuation
Jazz Pharmaceuticals has an Enterprise Value (EV) of 11.36B.
| EV / Sales | 2.79 |
| EV / EBITDA | 8.3 |
| EV / EBIT | 8.14 |
| EV / FCF | 8.43 |
Financial Position
The company has a current ratio of 4.46,
with a Debt / Equity ratio of 1.51.
| Current Ratio | 4.46 |
| Quick Ratio | 3.99 |
| Debt / Equity | 1.51 |
| Debt / EBITDA | 4.5 |
| Debt / FCF | 4.57 |
| Interest Coverage | 3.01 |
Financial Efficiency
Return on Equity is 13.68% and Return on Invested Capital is 7.74%.
| Return on Equity | 13.68% |
| Return on Assets | 4.66% |
| Return on Invested Capital | 7.74% |
| Revenue Per Employee | $1,453,196.43 |
| Profits Per Employee | $200,042.86 |
| Employee Count | 2,800 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.93 |
Taxes
| Income Tax | -89.77M |
| Effective Tax Rate | -19.09% |
Stock Price Statistics
The stock price has increased by 2.63% in the
last 52 weeks. The beta is 0.38, so Jazz Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | 2.63% |
| 50-Day Moving Average | 113.05 |
| 200-Day Moving Average | 118.49 |
| Relative Strength Index (RSI) | 48.29 |
| Average Volume (20 Days) | 1,321,709 |
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of 4.07B
and earned 560.12M
in profits. Earnings per share was 9.06.
| Revenue | 4.07B |
| Gross Profit | 3.62B |
| Operating Income | 716.63M |
| Net Income | 560.12M |
| EBITDA | 1.37B |
| EBIT | 708.45M |
| Earnings Per Share (EPS) | 9.06 |
Full Income StatementBalance Sheet
The company has 2.41B in cash and 6.16B in
debt, giving a net cash position of -3.75B.
| Cash & Cash Equivalents | 2.41B |
| Total Debt | 6.16B |
| Net Cash | -3.75B |
| Retained Earnings | 1.13B |
| Total Assets | 11.53B |
| Working Capital | 2.91B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 1.4B
and capital expenditures -48.07M, giving a free cash flow of 1.35B.
| Operating Cash Flow | 1.4B |
| Capital Expenditures | -48.07M |
| Free Cash Flow | 1.35B |
| FCF Per Share | 21.8 |
Full Cash Flow StatementMargins
Gross margin is 89.05%, with operating and profit margins of 17.61% and 13.77%.
| Gross Margin | 89.05% |
| Operating Margin | 17.61% |
| Pretax Margin | 11.56% |
| Profit Margin | 13.77% |
| EBITDA Margin | 33.63% |
| EBIT Margin | 17.61% |
| FCF Margin | 33.12% |
